Stockreport

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences, Inc.  (IGMS) 
Last igm biosciences, inc. earnings: 3/26 04:05 pm Check Earnings Report
PDF – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (C [Read more]